SCHEMBL6168528

SCHEMBL6168528

Cc1nc2ccc(C(=O)NCc3ccccn3)cc2n1CCc1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.59
ALDH1A1 P00352 4/20 0.59
GAA P10253 2/20 0.59
HTT P42858 2/20 0.59
SMN1; SMN2 Q16637 2/20 0.59
GLA P06280 1/20 0.59
NAMPT P43490 1/20 0.57
PDE2A O00408 2/20 0.53
PIK3CA P42336 1/20 0.52
POLB P06746 3/20 0.50
TDP1 Q9NUW8 3/20 0.50
MEN1 O00255 3/20 0.50
KMT2A Q03164 3/20 0.50
MAPT P10636 2/20 0.50
L3MBTL1 Q9Y468 2/20 0.50
HPGD P15428 2/20 0.50
ALOX15 P16050 2/20 0.50
HSD17B10 Q99714 2/20 0.50
THRB P10828 1/20 0.50
PKM P14618 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6169101 0.92 KDM4E (0.59) KDM4EALDH1A1GAAHTTSMN1; SMN2
SCHEMBL6170298 0.90 PPARG (0.58) KDM4EALDH1A1GAAHTTSMN1; SMN2
SCHEMBL6170887 0.85 LMNA (0.58) KDM4EALDH1A1HTTSMN1; SMN2GLA
SCHEMBL6171906 0.83 PPARG (0.53) KDM4ESMN1; SMN2NAMPTPDE2APIK3CA
SCHEMBL6171876 0.83 PPARG (0.52) KDM4EALDH1A1GLANAMPTPDE2A
SCHEMBL6169196 0.83 PDE2A (0.53) KDM4EALDH1A1GLANAMPTPDE2A
SCHEMBL6169021 0.83 KDM4E (0.54) KDM4EALDH1A1NAMPTPDE2APIK3CA
SCHEMBL6169338 0.81 ALDH1A1 (0.55) KDM4EALDH1A1HTTGLANAMPT
SCHEMBL6169216 0.81 PPARG (0.67) KDM4EALDH1A1GLANAMPTPDE2A
SCHEMBL6170433 0.81 KMT2A (0.61) KDM4EALDH1A1GAAGLANAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0882718-B1 BENZIMIDAZOLE DERIVATIVES FUJISAWA PHARMACEUTICAL CO (JP) 2005-08-31 EP disclosed
US-20020082280-A1 Method of inhibiting neoplastic cells with benzimidazole derivatives OSI PHARMACEUTICALS, INC. 2002-06-27 US disclosed
US-6352985-B1 CARDIOVASCULAR DISORDERS OR GASTROINTESTINAL DISORDERS, DIABETES (TYPE II DIABETES), DIABETIC COMPLICATIONS METHOD FOR LOWERING THE BLOOD SUGAR LEVEL OF A PATIENT, FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-03-05 US disclosed
US-6348032-B1 POTENT COMPOUNDS THAT INDUCE APOPTOSIS IN NEOPLASTIC CELLS (BUT NOT SUBSTANTIALLY IN NORMAL CELLS), WITHOUT SUBSTANTIALLY INHIBITING PGE-2. CELL PATHWAYS, INC. 2002-02-19 US disclosed
US-6166219-A Benzimidazole derivatives FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-12-26 US disclosed
EP-0882718-A1 BENZIMIDAZOLE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1998-12-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020082280-A1 Method of inhibiting neoplastic cells with benzimidazole derivatives MKI67, CCNI, TMBIM6 KDM4E 2132/4885ALDH1A1 487/4885GAA 708/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.